Dmitry Byk, MD
Psychiatry · Davie, FLNPI 1194826511
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $54,320 of the $69,929 with a category attached, or 77.7%. AbbVie accounts for 84.4% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2019 at $22,536 and has fallen 97.0% since, to $685 in 2025. Among psychiatry clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 596 payments — averaging $117.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$59K
- Bausch Health US, LLC$2K
- Vanda Pharmaceuticals Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Lundbeck LLC$1K
- Takeda Pharmaceuticals U.S.A., Inc.$725
- plus $4K from 21 others
What the payments were for
- Consulting fees$2,0133%
- Speaking & faculty fees$54,32078%
- Travel & lodging$1,7653%
- Food & beverage$11,68317%
- Education$1480%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 198 | $59,052 |
| Bausch Health US, LLC | 22 | $2,419 |
| Vanda Pharmaceuticals Inc. | 60 | $1,331 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 45 | $1,330 |
| Lundbeck LLC | 53 | $1,028 |
| Takeda Pharmaceuticals U.S.A., Inc. | 41 | $725 |
| Teva Pharmaceuticals USA, Inc. | 25 | $721 |
| Otsuka America Pharmaceutical, Inc. | 28 | $607 |
| Axsome Therapeutics, Inc. | 22 | $583 |
| Johnson & Johnson | 17 | $564 |
| Alkermes, Inc. | 29 | $489 |
| Neurocrine Biosciences, Inc. | 11 | $274 |
| Tris Pharma Inc | 15 | $270 |
| Sunovion Pharmaceuticals Inc. | 7 | $112 |
| Adlon Therapeutics L.p. | 5 | $78 |
| Idorsia Pharmaceuticals US Inc | 3 | $66 |
| Orexo US, Inc. | 2 | $44 |
| Shire North American Group Inc | 2 | $40 |
| Almatica Pharma LLC | 2 | $39 |
| Alfasigma USA, Inc. | 2 | $33 |
| Livanova USA, Inc. | 1 | $21 |
| Corium, LLC | 1 | $20 |
| Eisai Inc. | 1 | $19 |
| Ironshore Pharmaceuticals Inc. | 1 | $19 |
| Vertical Pharmaceuticals, LLC | 1 | $18 |
| Avanir Pharmaceuticals, Inc. | 1 | $16 |
| Merck | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$69,929 in reported general payments places this provider in the 95th percentile of 2,059 psychiatry providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 46 | $67,953 |
| Invega SustennaPaliperidone Palmitate | 13 | $28,566 |
| AuvelityDextromethorphan Hbr/Bupropion | 21 | $19,927 |
| TrintellixVortioxetine Hydrobromide | 25 | $14,940 |
| Lurasidone Hcl | 29 | $9,064 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 68 | $1,885 |
| Escitalopram Oxalate | 133 | $1,256 |
| Olanzapine OdtOlanzapine | 17 | $1,211 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 14 | $1,026 |
| Bupropion XlBupropion Hcl | 64 | $923 |
| Vilazodone Hcl | 12 | $561 |
| Duloxetine Hcl | 34 | $519 |
| Quetiapine Fumarate | 62 | $481 |
| Divalproex Sodium | 30 | $448 |
| Zolpidem Tartrate | 80 | $437 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $59,052 | $67,95346 claims |
| Johnson & JohnsonInvega Sustenna | $564 | $28,56613 claims |
| Axsome Therapeutics, Inc.Auvelity | $583 | $19,92721 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $725 | $14,94025 claims |
| Almatica Pharma LLCSertraline Hcl | $39 | $43342 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,059 psychiatry providers in Florida.
Other psychiatry in Davie
- Andrew CutlerLakewood Ranch$5.7M
- Richard JacksonBoca Raton$3.6M
- Ilan MelnickCoral Gables$2.8M
- Todd BroderSt Augustine$1.6M
- Heather LuingSaint Augustine$1.5M
- Todd GatesWest Melbourne$1.2M
- Lawrence ReccoppaGainesville$968K
- Thomas ValenteLeesburg$967K
- Michelle ScargleClearwater$926K
- David SheehanTampa$631K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.